Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Urothelial Cancer × Docetaxel × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 126 Carcinoma, Non-Small-Cell Lung 92 Prostatic Neoplasms 45 Lung Neoplasms 29 Neoplasm Metastasis 18 Stomach Neoplasms 16 Nasopharyngeal Carcinoma 16 Parkinson Disease 4, Autosomal Dominant Lewy Body 14 Neoplasms 14 Squamous Cell Carcinoma of Head and Neck 12 Esophageal Neoplasms 10 Urinary Bladder Neoplasms 7 Head and Neck Neoplasms 7 Esophageal Squamous Cell Carcinoma 7 Ovarian Neoplasms 6 Carcinoma 6 Adenocarcinoma 6 Fallopian Tube Neoplasms 5 Carcinoma, Squamous Cell 5 Recurrence 4 Inflammatory Breast Neoplasms 4 HER2-positive Breast Cancer 4 Endometrial Neoplasms 4 Carcinoma, Transitional Cell 4 Adenocarcinoma of Lung 4 Adenocarcinoma Of Esophagus 4 Triple Negative Breast Neoplasms 3 Primary Breast Cancer 3 Carcinoma, Ovarian Epithelial 3 Uterine Cervical Neoplasms 2

Interventions

Gemcitabine 3 Cisplatin 3 Carboplatin 3 pembrolizumab 2 vinflunine 1 tremelimumab 1 erdafitinib 1 enfortumab vedotin 1 durvalumab 1 Nivolumab 1 Ipilimumab 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03390504 2026-02-02

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting

629 enrolled 32 charts 1 FDA

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡